NCT06867107

A Long-term Follow-up Study for Participants That Completed the SAT-3247-CL-101 Study

An Open-Label Long-Term Follow-up Study of SAT-3247 in Patients With Duchenne Muscular Dystrophy (DMD) That Participated in SAT-3247-CL-101

• Status: Enrolling By Invitation
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (estimated)
• Sponsor: Satellos Bioscience, Inc. · Industry
• Sex: Male
• Age: 18 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label long-term safety and efficacy study of orally administered SAT-3247 in patients with DMD that previously participated in SAT-3247-CL-101. The study will assess the long-term safety, tolerability and potential efficacy of long-term dosing of 60 mg of orally administered SAT-3247 in a 5-days on/2-days off (i.e. weekday dosing) regimen in an open-label design through 11 months- for a total of 12 months of treatment including the duration of the SAT-3247-CL-101 study. The study will enroll up to 10 participants that previously participated in the SAT-3247-CL-101 study.

Conditions

• Duchenne Muscular Dystrophy (DMD)

Interventions

Type	Name	Description
DRUG	SAT-3247	AAK1 inhibitor

Timeline

• Start date: 2025-08-20
• Primary completion: 2026-08-30
• Completion: 2026-08-30
• First posted: 2025-03-10
• Last updated: 2025-09-10

Locations

1 site across 1 country: Australia